Kidney cancer: The cytokine working group experience (1986–2001): Part II: Management of IL-2 toxicity and studies with other cytokines

Author： Dutcher Janice Atkins Michael Margolin Kim Weiss Geoff Clark Joseph Sosman Jeff Logan Theodore Aronson Fred Mier James

Publisher： Humana Press, Inc

ISSN： 1357-0560

Source： Medical Oncology, Vol.18, Iss.3, 2001-09, pp. : 209-219

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Kidney cancer: The cytokine working group experience (1986–2001): Part I. IL-2-based clinical trials

By Atkins Michael Dutcher Janice Weiss Geoff Margolin Kim Clark Joseph Sosman Jeff Logan Theodore Aronson Fred Mier James

Medical Oncology, Vol. 18, Iss. 3, 2001-09 ,pp. : 197-207

Humana Press, Inc

Access to resources Recommend Favorite

Phase II trial of interleukin 2, interferon , and 5-fluorouracil in metastatic renal cell cancer - a cytokine working group study.

By Dutcher J. Logan T. Gordon M. Sosman J. Weiss G. Margolin K. Plasse T. Mier J. Lotze M. Clark J. Atkins M.

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. : 83-84

Elsevier

Access to resources Recommend Favorite

Part II: Testicular cancer-management of advanced disease

By Jones R.H. Vasey P.A.

Lancet Oncology, Vol. 4, Iss. 12, 2003-12 ,pp. : 738-747

Elsevier

Access to resources Recommend Favorite

Diagnosis and local management of breast cancer: part II

By Benson John R

Future Oncology, Vol. 7, Iss. 8, 2011-08 ,pp. : 959-961

Future Medicine

Access to resources Recommend Favorite

Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?

By Kirkali Ziya Tüüzel Emre

Future Oncology, Vol. 5, Iss. 6, 2009-08 ,pp. : 871-888

Future Medicine

Access to resources Recommend Favorite